000 | 01884 a2200529 4500 | ||
---|---|---|---|
005 | 20250515011742.0 | ||
264 | 0 | _c20060124 | |
008 | 200601s 0 0 eng d | ||
022 | _a0270-9139 | ||
024 | 7 |
_a10.1002/hep.21006 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aDing, Xiaokun | |
245 | 0 | 0 |
_aExendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. _h[electronic resource] |
260 |
_bHepatology (Baltimore, Md.) _cJan 2006 |
||
300 |
_a173-81 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAdipose Tissue _xmetabolism |
650 | 0 | 4 |
_aAlanine Transaminase _xblood |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aBlood Glucose _xanalysis |
650 | 0 | 4 |
_aCyclic AMP _xbiosynthesis |
650 | 0 | 4 | _aExenatide |
650 | 0 | 4 |
_aFatty Liver _xdrug therapy |
650 | 0 | 4 |
_aGlucagon-Like Peptide 1 _xpharmacology |
650 | 0 | 4 | _aGlucagon-Like Peptide-1 Receptor |
650 | 0 | 4 | _aInsulin Resistance |
650 | 0 | 4 |
_aLipid Peroxidation _xdrug effects |
650 | 0 | 4 |
_aLiver _xmetabolism |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Obese |
650 | 0 | 4 |
_aPPAR alpha _xgenetics |
650 | 0 | 4 |
_aPeptides _xtherapeutic use |
650 | 0 | 4 |
_aRNA, Messenger _xanalysis |
650 | 0 | 4 |
_aReceptors, Glucagon _xagonists |
650 | 0 | 4 |
_aStearoyl-CoA Desaturase _xgenetics |
650 | 0 | 4 |
_aSterol Regulatory Element Binding Protein 1 _xgenetics |
650 | 0 | 4 |
_aVenoms _xtherapeutic use |
650 | 0 | 4 |
_aWeight Gain _xdrug effects |
700 | 1 | _aSaxena, Neeraj K | |
700 | 1 | _aLin, Songbai | |
700 | 1 | _aGupta, Nitika Arora | |
700 | 1 | _aGupta, Narita | |
700 | 1 | _aAnania, Frank A | |
773 | 0 |
_tHepatology (Baltimore, Md.) _gvol. 43 _gno. 1 _gp. 173-81 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1002/hep.21006 _zAvailable from publisher's website |
999 |
_c15993485 _d15993485 |